Mechanism of action
Zolbetuximab is the first drug developed against the target of Claudin18.2. It is a chimeric IgG1 monoclonal antibody that specifically binds to Claudin18.2 on the surface of tumor cells, thereby triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis and inhibition of cell proliferation.
